Hypertension Drug Therapy Management

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/34

encourage image

There's no tags or description

Looks like no tags are added yet.

35 Terms

1
New cards

Furosemide (Lasix)

Drug Class: Loop diuretic. Clinical Indication: Fluid overload, edema, and blood pressure reduction in advanced kidney disease. Key Monitoring: Serum potassium (hypokalemia), serum creatinine/eGFR\text{eGFR}, and ototoxicity/hearing loss in high-risk patients.

2
New cards

Amlodipine (Norvasc)

Drug Class: Long-acting dihydropyridine calcium channel blocker (DHP-CCB\text{DHP-CCB}). Clinical Indication: First-line agent for uncomplicated hypertension. Key Adverse Effect: Dose-dependent lower extremity peripheral edema (vasodilatory, not fluid overload).

3
New cards

Metoprolol Tartrate (Lopressor)

Drug Class: Second-generation β1\beta_1-selective adrenergic antagonist. Formulation/Dosing: Regular/immediate-release requiring twice-daily (BID\text{BID}) administration.

4
New cards

Metoprolol Succinate (Toprol XL)

Drug Class: Second-generation β1\beta_1-selective adrenergic antagonist. Formulation/Dosing: Extended-release (ER\text{ER}) formulation providing once-daily (QD\text{QD}) coverage for hypertension and heart failure.

5
New cards

Carvedilol (Coreg)

Drug Class: Third-generation non-selective β\beta-blocker with α1\alpha_1-adrenoceptor blocking properties. Clinical Indication: Preferred in heart failure and post-myocardial infarction (MI\text{MI}).

6
New cards

Diltiazem (Cardizem)

Drug Class: Non-dihydropyridine calcium channel blocker (non-DHP-CCB\text{non-DHP-CCB}). Clinical Indication: Ventricular rate control in atrial fibrillation and angina; excluded from first-line status for uncomplicated hypertension.

7
New cards

Losartan (Cozaar)

Drug Class: Angiotensin II receptor blocker (ARB\text{ARB}). Clinical Indication: First-line for uncomplicated hypertension and preferred in diabetic nephropathy/albuminuria (≥30 mg/g\ge 30\,\text{mg/g}); alternative for patients with ACEI\text{ACEI}-induced cough.

8
New cards

Valsartan (Diovan)

Drug Class: Angiotensin II receptor blocker (ARB\text{ARB}). Clinical Indication: First-line for uncomplicated hypertension, chronic coronary disease, and heart failure.

9
New cards

Triamterene / Hydrochlorothiazide (Dyazide)

Drug Class: Combination potassium-sparing diuretic and thiazide diuretic. Mechanism: Offsets thiazide-induced urinary potassium wasting while providing synergistic natriuresis.

10
New cards

Valsartan / Sacubitril (Entresto)

Drug Class: Angiotensin receptor-neprilysin inhibitor (ARNI\text{ARNI}). Clinical Indication: Heart failure with reduced ejection fraction (HFrEF\text{HFrEF}); requires a 36-hour36\text{-hour} washout period if transitioning from an ACEI\text{ACEI} to prevent severe angioedema.

11
New cards

Dapagliflozin (Farxiga)

Drug Class: Sodium-glucose cotransporter 22 (SGLT2\text{SGLT2}) inhibitor. Clinical Indication: Heart failure, type 22 diabetes, and chronic kidney disease (CKD\text{CKD}). Key Monitoring: Baseline and routine SCr/eGFR\text{SCr/eGFR} and serum potassium.

12
New cards

Empagliflozin (Jardiance)

Drug Class: Sodium-glucose cotransporter 22 (SGLT2\text{SGLT2}) inhibitor. Clinical Indication: Type 22 diabetes and heart failure. Key Monitoring: Renal function (eGFR\text{eGFR}) and volume status.

13
New cards

Blood Pressure Staging: Normal Blood Pressure

Systolic blood pressure (SBP\text{SBP}) <120 mmHg< 120\,\text{mmHg} and diastolic blood pressure (DBP\text{DBP}) <80 mmHg< 80\,\text{mmHg}.

14
New cards

Blood Pressure Staging: Stage 1 Hypertension

SBP 130–139 mmHg\text{SBP } 130\text{--}139\,\text{mmHg} or DBP 80–89 mmHg\text{DBP } 80\text{--}89\,\text{mmHg}. Diagnosis requires confirmed average readings across at least 22 separate clinical encounters.

15
New cards

Blood Pressure Staging: Stage 2 Hypertension

SBP≥140 mmHg\text{SBP} \ge 140\,\text{mmHg} or DBP≥90 mmHg\text{DBP} \ge 90\,\text{mmHg}.

16
New cards

Blood Pressure Staging: Discordant Category Rule

When systolic and diastolic values fall into different diagnostic categories, the patient is classified definitively by the higher, more severe stage (e.g., 135/94 mmHg135/94\,\text{mmHg} is Stage 2 based on the DBP\text{DBP}).

17
New cards

Therapeutic Blood Pressure Target (20252025 Guidelines)

Primary goal for most treated patients is <130/80 mmHg< 130/80\,\text{mmHg}. An intensive goal of SBP<120 mmHg\text{SBP} < 120\,\text{mmHg} can be considered for select high-risk patients if clinically tolerated.

18
New cards

First-Line Antihypertensive Classes for Uncomplicated Hypertension

1.1. Thiazide-type/thiazide-like diuretics, 2.2. Long-acting dihydropyridine calcium channel blockers (DHP-CCBs\text{DHP-CCBs}), 3.3. Angiotensin-converting enzyme inhibitors (ACEIs\text{ACEIs}), 4.4. Angiotensin receptor blockers (ARBs\text{ARBs}). Note: β\beta-blockers and non-DHP-CCBs\text{non-DHP-CCBs} are not first-line for uncomplicated disease.

19
New cards

Pharmacotherapy Initiation: Stage 1 vs. Stage 2 Hypertension

Stage 2 (≥140/90 mmHg\ge 140/90\,\text{mmHg}): Start immediately with 22 first-line agents from different classes (single-pill fixed-dose combination preferred). Stage 1 (130–139/80–89 mmHg130\text{--}139/80\text{--}89\,\text{mmHg}): Start monotherapy if high-risk (clinical CVD\text{CVD}, diabetes, CKD\text{CKD}, or PREVENT-CVD 10-year risk≥7.5%\text{PREVENT-CVD } 10\text{-year risk} \ge 7.5\%); initiate 3 to 6 months3\text{ to } 6\,\text{months} of lifestyle modifications if low-risk (<7.5%< 7.5\%).

20
New cards

Contraindication: Dual RAAS Inhibition

Simultaneous co-administration of an ACEI\text{ACEI} with an ARB\text{ARB} or direct renin inhibitor is strictly contraindicated due to increased risk of hyperkalemia, acute kidney injury, and profound hypotension without added clinical benefit.

21
New cards

Preferred Antihypertensives: Diabetes Mellitus with CKD / Albuminuria

ACEIs\text{ACEIs} or ARBs\text{ARBs} are preferred first-line when diabetes presents with eGFR<60 mL/min/1.73 m2\text{eGFR} < 60\,\text{mL/min/1.73 m}^2 or persistent albuminuria (urine albumin-to-creatinine ratio≥30 mg/g\text{urine albumin-to-creatinine ratio} \ge 30\,\text{mg/g}) due to renal protective benefits.

22
New cards

Preferred Antihypertensives: Chronic Coronary Disease / Post-MI

β\beta-blockers, ACEIs\text{ACEIs}, and ARBs\text{ARBs} are elevated to first-line status due to proven reductions in cardiovascular mortality and re-infarction risk.

23
New cards

Preferred Antihypertensives: Atrial Fibrillation

β\beta-blockers are preferred initial agents to provide ventricular rate control while concurrently decreasing systemic blood pressure.

24
New cards

Preferred Antihypertensives: Prior Stroke / Cerebrovascular Disease

A thiazide-type diuretic, an ACEI\text{ACEI}, or an ARB\text{ARB} is preferred for secondary stroke prevention; calcium channel blockers are de-emphasized.

25
New cards

Hypertension in Pregnancy: Preferred Outpatient Medications

Oral labetalol and extended-release (ER\text{ER}) nifedipine are the primary first-line therapies; oral methyldopa is a secondary alternative.

26
New cards

Hypertension in Pregnancy: Acute Inpatient Emergency Management

Intravenous (IV\text{IV}) labetalol, intravenous (IV\text{IV}) hydralazine, and immediate-release oral nifedipine.

27
New cards

Hypertension in Pregnancy: Absolute Contraindications

All RAAS\text{RAAS} inhibitors (ACEIs\text{ACEIs}, ARBs\text{ARBs}, direct renin inhibitors), mineralocorticoid receptor antagonists (MRAs\text{MRAs}: spironolactone, eplerenone), atenolol (associated with severe fetal growth restriction), and sodium nitroprusside (fetal cyanide poisoning).

28
New cards

Definition of Resistant Hypertension

Blood pressure uncontrolled (≥130/80 mmHg\ge 130/80\,\text{mmHg}) despite verified adherence to maximally tolerated doses of 33 complementary antihypertensive classes (including a diuretic), OR blood pressure controlled (<130/80 mmHg< 130/80\,\text{mmHg}) requiring ≥4\ge 4 distinct antihypertensive medications.

29
New cards

Pseudoresistant Hypertension Causes

1.1. Medication non-adherence (most common cause), 2.2. Incorrect blood pressure measurement technique (improper cuff size, talking, lack of back/arm support), 3.3. White Coat effect. Pseudoresistance must be ruled out before intensifying pharmacotherapy.

30
New cards

Interfering Substances that Elevate Blood Pressure

NSAIDs\text{NSAIDs} (blunt prostaglandin synthesis and diuretic efficacy), oral/topical nasal decongestants (pseudoephedrine, phenylephrine, oxymetazoline), systemic corticosteroids, stimulants, caffeine, nicotine, and heavy alcohol intake.

31
New cards

Stepwise Management of Resistant Hypertension

Step 1: Maximize diuretic therapy (switch HCTZ\text{HCTZ} to longer-acting chlorthalidone or indapamide; switch to loop diuretics in advanced CKD\text{CKD}). Step 2: Add an MRA\text{MRA} (spironolactone or eplerenone) after verifying adequate eGFR\text{eGFR} and normal serum potassium. Step 3: Add complementary agents (β\beta-blockers, non-DHP-CCBs\text{non-DHP-CCBs}, or central α2\alpha_2-agonists like clonidine). Step 4: Add direct vasodilators (hydralazine, minoxidil, aprocitentan).

32
New cards

Chlorthalidone vs. Hydrochlorothiazide (HCTZ)

Chlorthalidone has a significantly longer elimination half-life and greater milligram-for-milligram potency compared to hydrochlorothiazide, making it the preferred substitution for inadequate blood pressure response.

33
New cards

Key Monitoring Parameters: Thiazide Diuretics

Blood pressure efficacy, serum potassium (risk of hypokalemia), serum sodium (hyponatremia), serum calcium (hypercalcemia), blood glucose (hyperglycemia), uric acid (hyperuricemia / gout flares), and SCr/eGFR\text{SCr/eGFR}.

34
New cards

Key Monitoring Parameters: ACE Inhibitors and ARBs

Blood pressure efficacy, serum potassium (risk of hyperkalemia), SCr/eGFR\text{SCr/eGFR} (acute kidney injury), angioedema risk, and persistent dry non-productive cough (ACEI\text{ACEI}-specific, mediated by bradykinin; managed by switching to an ARB\text{ARB}).

35
New cards

Clinical Pearl: Regimen Simplification and Medication Timing

Switch captopril (BID/TID\text{BID/TID}) to once-daily lisinopril; switch metoprolol tartrate (BID\text{BID}) to once-daily metoprolol succinate; administer potent loop diuretics (e.g., furosemide) in the morning or after breakfast rather than in the evening (8:00 PM8:00\,\text{PM}) to prevent nocturia and sleep fragmentation.